Evidence map›Paper›PMID 37631156›Full record

ReviewPlants (Basel, Switzerland)2023

New Insights into the Latest Advancement in α-Amylase Inhibitors of Plant Origin with Anti-Diabetic Effects.

Hamdy Kashtoh, Kwang-Hyun Baek

Open access · goldAbstract readReview
In one paragraph

Review in Plants (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
28.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 144 citations in OpenAlex.

  1. Article
  2. Article
  3. GC-Ms, UHPLC-MS/MSChemistry & biodiversity · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Phytochemical Characterisation and Bioactivity ofMolecules (Basel, Switzerland) · 2026
    Article
  13. Phytochemical Profile and Bioactive Potential ofCurrent issues in molecular biology · 2026
    Article
  14. Article
  15. Article
  16. Seasonal Variation in WildMolecules (Basel, Switzerland) · 2026
    Article
  17. Review
  18. Article
  19. Article
  20. Therapeutic Potential of White Kidney Beans (Foods (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Hamdy KashtohDepartment of Biotechnology, Yeungnam University, Gyeongsan 38541, Republic of Korea.
Kwang-Hyun BaekDepartment of Biotechnology, Yeungnam University, Gyeongsan 38541, Republic of Korea.ORCID 0000-0002-6719-9187
Yeungnam University · KR

Funding

National Research Foundation of Korea NRF-2021R1F1A1060297
6 · The paper itself

Abstract

The rising predominance of type 2 diabetes, combined with the poor medical effects seen with commercially available anti-diabetic medications, has motivated the development of innovative treatment approaches for regulating postprandial glucose levels. Natural carbohydrate digestion enzyme inhibitors might be a viable option for blocking dietary carbohydrate absorption with fewer side effects than manufactured medicines. Alpha-amylase is a metalloenzyme that facilitates digestion by breaking down polysaccharides into smaller molecules such as maltose and maltotriose. It also contributes to elevated blood glucose levels and postprandial hyperglycemia. As a result, scientists are being urged to target α-amylase and create inhibitors that can slow down the release of glucose from carbohydrate chains and prolong its absorption, thereby resulting in lower postprandial plasma glucose levels. Natural α-amylase inhibitors derived from plants have gained popularity as safe and cost-effective alternatives. The bioactive components responsible for the inhibitory actions of various plant extracts have been identified through phytochemical research, paving the way for further development and application. The majority of the findings, however, are based on in vitro investigations. Only a few animal experiments and very few human investigations have confirmed these findings. Despite some promising results, additional investigation is needed to develop feasible anti-diabetic drugs based on plant-derived pancreatic α-amylase inhibitors. This review summarizes the most recent findings from research on plant-derived pancreatic α-amylase inhibitors, including plant extracts and plant-derived bioactive compounds. Furthermore, it offers insights into the structural aspects of the crucial therapeutic target, α-amylases, in addition to their interactions with inhibitors.

Indexed as

alpha-amylaseanti-diabetic activityextractnatural compoundspostprandial hyperglycemiatype 2 diabetes

Identifiers

PMID37631156
PMCPMC10458243
OpenAlexW4385835176

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.